InvestorsHub Logo
Followers 137
Posts 5060
Boards Moderated 0
Alias Born 01/31/2012

Re: None

Wednesday, 11/28/2018 9:38:15 AM

Wednesday, November 28, 2018 9:38:15 AM

Post# of 50195
$NXEN NEWS! Collaboration with Ivy League Medical School!

https://globenewswire.com/news-release/2018/11/28/1658294/0/en/Nexien-BioPharma-And-Ivy-League-University-Medical-School-Collaborate-On-Pre-Clinical-Cannabinoid-Studies.html

Nexien BioPharma Inc. (OTC QB: NXEN) (“Nexien” or the “Company”) announced it is initiating a collaboration with the University Medical School (the “Medical School”) to perform pre-clinical studies using advanced parenteral cannabinoid formulations developed by Nexien, known as NX01R1, NX01R2, and NX01R3 (“formulations”). These formulations target the alleviation of symptoms for the acute treatment and intervention of convulsive disorders and convulsive episodes.

Parenteral administration is a route of administration that includes intramuscular injections of the formulations for optimal dosing and bio-availability. Parenteral administration excludes oral administration of drug formulations.

Nexien will provide the Medical School’s Neurology Lab with specific formulations, in addition to a comprehensive study design developed by the Company’s scientific team. This pre-clinical research will be first performed in rodents, and will initially investigate the Maximum Tolerable Dose (“MTD”) Pharmacokinetic (“PK”) and Pharmacodynamic (“PD”) profiles of advanced cannabinoid-based parenteral formulations.

In November 2017, Nexien filed a provisional patent application with the United States Patent and Trademark Office (USPTO) relating to the use of cannabinoids to treat convulsive disorders, specifically epilepsy and refractory epilepsy. Refractory epilepsy is a form of epilepsy in which patients typically do not respond to existing available medications and treatment options.

“Nexien is very excited to be working with such a prestigious Medical School. Specifically, we’re working with the Neurology Department which is chaired by a renowned Epileptologist,” said Alex Wasyl, Chief Executive Officer of Nexien.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.